Adhera Therapeutics Inc (ATRX)

[Jose Chavez]

$ATRX “MLR-1019 represents what could be a huge step forward in the field of Parkinson’s disease insomuch that we’re optimistic it can provide patients relief for both movement and non-movement symptoms,” said Andrew Kucharchuk, Chief Executive Officer at Adhera. “We are thrilled to have the Melior group of companies as partners and collaborators on this project and look forward to evaluating MLR-1019 in a clinical setting with the goal of delivering a safe and effective option to patients and neurologists to better manage this debilitating disease.”